In Vivo
Drug companies pay MCO's too much in rebates and get too little in return—but "fair share" analysis can help, for some drugs, drive as much as $100 million in additional revenues.
Drug companies pay MCO's too much in rebates and get too little in return—but "fair share" analysis can help, for some drugs, drive as much as $100 million in additional revenues.